Company intelligence / Profile preview

Lumus

Austin, Texas, United Stateslumusimaging.com.au ↗

Ownership: Private
Development stage: Commercial

Overview

Topline data from Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM‑201 in Pediatric Growth Hormone Deficiency met all primary and secondary endpoints, demonstrating sustained growth over 24 months and correlation to LUM‑201’s unique pulsatile mechanism of action.

Therapeutic areas: GastroenterologyEndocrinologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Massachusetts General Hospital

Beyond the preview

Go deeper on Lumus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumus.

Explore the full profile